Neuroinvasive Bacillus cereus Infection Amongst Immunocompromised Patients: Epidemiologic Investigation of 5 Cases in Patients with Acute Myeloid Leukemia
Jessica S Little,Cassie Coughlin,Candace Hsieh,Meaghan Lanza,Wan Yi Huang,Aishwarya Kumar,Tanvi Dandawate,Robert Tucker,Paige Gable,Axel A Vazquez Deida,Heather Moulton-Meissner,Valerie Stevens,Gillian McAllister,Thomas Ewing,Maria Diaz,Janet Glowicz,Marisa L Winkler,Nicole Pecora,David W Kubiak,Jeffrey C Pearson,Marlise R Luskin,Amy C Sherman,Ann E Woolley,Christina Brandeburg,Barbara Bolstorff,Eileen McHale,Esther Fortes,Matthew Doucette,Sandra Smole,Craig Bunnell,Anne Gross,Dana Platt,Sonali Desai,Karen Fiumara,Nicolas C Issa,Lindsey R Baden,Chanu Rhee,Michael Klompas,Meghan A Baker
DOI: https://doi.org/10.1093/ofid/ofae048
2024-01-25
Open Forum Infectious Diseases
Abstract:Abstract Introduction Bacillus cereus is a ubiquitous gram-positive rod-shaped bacterium that can cause sepsis and neuroinvasive disease in patients with acute leukemia or neutropenia. Methods A single-center, retrospective review was conducted to evaluate patients with acute leukemia, positive blood or cerebrospinal fluid testing for B. cereus, and abnormal neuroradiographic findings between January 2018 and October 2022. Infection control practices were observed, environmental samples obtained, a dietary case-control study completed, and whole genome sequencing performed on environmental and clinical Bacillus isolates. Results Five patients with B. cereus neuroinvasive disease were identified. All patients had acute myeloid leukemia (AML), were receiving induction chemotherapy, and were neutropenic. Neurologic involvement included subarachnoid or intraparenchymal hemorrhage or brain abscess. All patients were treated with ciprofloxacin and survived with limited or no neurologic sequelae. B. cereus was identified in 7/61 environmental and 1/19 dietary protein samples - these were unrelated to clinical isolates via sequencing. No point source was identified. Ciprofloxacin was added to the empiric antimicrobial regimen for AML patients with prolonged or recurrent neutropenic fevers; no new cases were identified in the ensuing year. Conclusions B. cereus is ubiquitous in the hospital environment, at times leading to clusters with unrelated isolates. Fastidious infection control practices addressing a broad range of possible exposures are warranted but their efficacy is unknown, and they may not be sufficient to prevent all infections. Thus, including B. cereus coverage in empiric regimens for AML patients with persistent neutropenic fever may limit the morbidity of this pathogen.
immunology,infectious diseases,microbiology